摘要
目的筛选丹酚酸B和丹参酮ⅡA保护高糖损伤肾细胞的最优配伍浓度。方法以高糖损伤的大鼠肾小球系膜细胞(HBZY-1)和人肾小管上皮细胞(HK-2)为研究对象,采用星点设计-响应面法,以细胞存活率为指标筛选丹酚酸B和丹参酮ⅡA的最优配伍浓度,并采用Elisa试剂盒对最优配伍浓度抗炎症因子(MCP-1、IL-6和TNF-α)的作用进行评价。结果保护高糖损伤HBZY-1和HK-2细胞的最优配伍浓度均为170.77μmol·L^(-1)丹酚酸B和0.27μmol·L^(-1)丹参酮ⅡA,细胞存活率分别为63.99%和54.42%,与预测值的偏差均小于2%。与模型组相比,最优配伍浓度组对HBZY-1细胞中MCP-1和HK-2细胞的TNF-α的下调作用显著(P<0.001),且均优于各自的单用组。结论170.77μmol·L^(-1)的丹酚酸B与0.27μmol·L^(-1)丹参酮ⅡA配伍对高糖损伤的肾细胞具有最佳保护作用,且抗炎作用良好。
OBJECTIVE To screen the optimal compatibility concentrations of salvianolic acid B and tanshinoneⅡA in protecting renal cells injured by high glucose.METHODS The star point design-response surface method was used to screen the optimal compatibility concentrations of salvianolic acid B and tanshinoneⅡA in protecting rat glomerular mesangial cells(HBZY-1 cells)and human tubular epithelial cells(HK-2 cells)injured by high glucose.Elisa kits of inflammatory factors(MCP-1,IL-6 and TNF-α)were used to evaluate the anti-inflammatory effect of the optimal compatibility concentration.RESULTS The optimal compatibility concentrations of salvianolic acid B and tanshinoneⅡA to protect HBZY-1 and HK-2 cells from high glucose injury were both 170.77μmol·L^(-1):0.27μmol·L^(-1).The cell survival rates were 63.99%and 54.42%,which were close to the predicted values.Compared with the model group,the concentrations of MCP-1,IL-6 and TNF-αin the cell supernatant of the model group were significantly increased(P<0.05),the optimal compatibility concentration group had significant downregulation effect on MCP-1 in HBZY-1 and TNF-αin HK-2(P<0.001)and was better than the respective single-use groups.CONCLUSION The optimal compatibility concentration ratio of salvianolic acid B and tanshinoneⅡA in protecting renal cells from high glucose injury is 170.77μmol·L^(-1):0.27μmol·L^(-1),which also has good anti-inflammatory effect.
作者
徐卓
张莘悦
宿树兰
段金廒
XU Zhuo;ZHANG Xin-yue;SU Shu-lan;DUAN Jin-ao(Jiangsu Provincial Key Laboratory of Formulary High-Tech Research,Jiangsu Provincial Collaborative Innovation Center for Industrialization of Traditional Chinese Medicine Resources,National and Local Joint Engineering Research Center for Traditional Chinese Medicine Resources Industrialization and Formula Innovative Drugs,Nanjing University of Chinese Medicine,Nanjing 210023,China)
出处
《中国药学杂志》
CAS
CSCD
北大核心
2023年第11期987-996,共10页
Chinese Pharmaceutical Journal
基金
国家自然科学基金项目资助(81973708)
南京中医药大学2021年江苏省研究生科研与实践创新计划项目资助(KYCX21_1760)。
作者简介
徐卓,女,博士研究生研究方向:中药化学与分析;通讯作者:宿树兰,女,博士,教授,博士生导师研究方向:中药资源化学与方剂功效物质及其作用机制Tel:(025)85811116;段金廒,男,博士,教授,博士生导师研究方向:中药资源化学及资源循环利用、中药功效物质与配伍关系Tel:(025)85811116。
